IV 
119TH CONGRESS 
1ST SESSION 
H. RES. 928 
Affirming support for most-favored-Nation drug pricing for United States 
patients. 
IN THE HOUSE OF REPRESENTATIVES 
DECEMBER 4, 2025 
Mrs. DINGELL (for herself and Mr. CRANE) submitted the following 
resolution; which was referred to the Committee on Energy and Commerce 
RESOLUTION 
Affirming support for most-favored-Nation drug pricing for 
United States patients. 
Whereas, according to a study conducted by the Department 
of Health and Human Services Office of the Assistant 
Secretary for Planning and Evaluation and RAND 
Health Care in 2024, the United States spends a higher 
and growing share of total drug spending on new drugs 
compared to other countries; 
Whereas the United States prices across all drugs, both 
brand name and generic, were nearly 2.78 times as high 
as prices in the comparison countries; 
Whereas, on average, according to the Organization for Eco-
nomic Cooperation and Development, United States citi-
zens spend over $1,400 on prescription drugs every year, 
the highest per capita drug spending in the world; 
VerDate Sep 11 2014 
02:45 Dec 05, 2025
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR928.IH
HR928
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 928 IH 
Whereas, according to polling done by the Kaiser Family 
Foundation, 21 percent of United States adults say they 
have not filled a prescription because of the cost, 23 per-
cent say they have instead opted for over-the-counter al-
ternatives, and 1 in 7 adults say they have cut pills in 
half or skipped doses of medicine in the last year because 
of the cost; 
Whereas lowering prescription drug prices to levels obtained 
in nations similar to the United States has long enjoyed 
bipartisan support from Congress and Presidential ad-
ministrations; 
Whereas, on May 12, 2025, President Trump signed an Ex-
ecutive order titled ‘‘Delivering Most-Favored-Nation 
Prescription Drug Pricing to American Patients’’ direct-
ing the Administration to take numerous actions to bring 
United States drug prices in line with those paid by simi-
lar nations; 
Whereas, on July 31, 2025, President Trump sent letters to 
leading pharmaceutical manufacturers outlining the steps 
they must take to bring down the prices of prescription 
drugs in the United States to match the lowest price of-
fered in other developed nations; and 
Whereas bipartisan Members of the 119th Congress have in-
troduced legislation that align with the goals of President 
Trump’s May 12, 2025, Executive order to align drug 
pricing for United States patients with the lowest price 
offered in other developed nations: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) supports the idea that patients in the 
United States should not be charged more than 
VerDate Sep 11 2014 
02:45 Dec 05, 2025
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\HR928.IH
HR928
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 928 IH 
those in other countries for the exact same prescrip-
tion drugs; 
(2) recognizes and affirms the commitment of 
the United States to reducing the cost of prescrip-
tion drugs for all United States citizens by— 
(A) supporting policies that align the pric-
ing of drugs sold in the United States with that 
of other developed nations; and 
(B) supporting other available methods, in-
cluding expanding Medicare drug price negotia-
tion and promoting price competition in the 
drug market; and 
(3) supports the idea that United States citi-
zens should have access to high-quality, affordable 
prescription drugs. 
Æ 
VerDate Sep 11 2014 
02:45 Dec 05, 2025
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\HR928.IH
HR928
kjohnson on DSK7ZCZBW3PROD with $$_JOB